•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.ONEOK to Acquire Brazos Midstream's Permian Midland Basin Assets for $4.425 Billion
Woodside Energy Half-Year Report for Period Ended 30 June 2026
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
NTG Clarity Networks Inc. (NCI:CA) Q1 2026 Earnings Call Transcript
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
Neo-Concept International Announces Share Consolidation
NTG Clarity Networks Inc. (NCI:CA) Q4 2025 Earnings Call Transcript
Rosen Law Firm Encourages Neo-Concept International Group Holdings Ltd. Investors to Inquire About Securities Class Action Investigation – NCI
Rosen Law Firm Encourages Neo-Concept International Group Holdings Ltd. Investors to Inquire About Securities Class Action Investigation – NCI
Reliance Industries to Fund $300B US Refinery: India ETFs in Focus
D. Boral Capital Acted as Lead Placement Agent to Neo-Concept International Group Holdings Limited (Nasdaq:NCI) in Connection with its ~$8,000,000 Follow-On Offering
Neo-Concept International Group Holdings Limited Announces Closing of Approximately US$8.1 Million Public Offering of Class A Ordinary Shares
Neo-Concept International Group Holdings Limited Announces Pricing of Approximately US$8.1 Million Public Offering of Class A Ordinary Shares
Neo-Concept International Group Holdings Limited Announces First Half 2025 Unaudited Financial Results
NTG Clarity Networks Inc. (NCI:CA) Q3 2025 Earnings Call Transcript
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia
Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025